



Dr Márcia Waddington-Cruz

CEPARM. National Amyloidosis Referral Center. Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro, Brazil

Dr Waddington-Cruz has also been responsible for the Brazilian referral centre for TTR-FAP, the Centro de Estudos em paramiloidose Antônio Rodrigues de Mello (CEPARM) since 1990. CEPARM oversees more than 400 TTR-FAP patients. Dr Waddington-Cruz participated in the development programme for tafamidis, patisiran, vutrisiran, inotersen, and eplontersen as well as serving on several Advisory Boards and Steering Committees in the field of ATTR.

CEPARM was the first amyloidosis referral centre established in Brazil and Dr. Waddington-Cruz faced several difficulties to create and maintain a multidisciplinary team devoted to amyloidosis.

She also struggled for the centre to have a space and equipment to properly receive patients coming from all over Latin America into the hard reality of the Public Health system.

Dr Waddington-Cruz was appointed President of the Transthyretin Amyloidosis Outcomes Survey (THAOS) scientific board in 2016 until 2019. She worked together with the Ministry of Health of Brazil for more than 4 years to write the first guidelines for treatment of Amyloidosis and to make tafamidis be included in the roll of drugs delivered by the Public Health system for Amyloidosis all over Brazil. Dr. Waddington-Cruz has been cooperating and working close with the patient's association (ABPAR) since its beginning back in 1989.